Literature DB >> 30405841

Preoperative Serum and Intra-platelet Serotonin in Prognosis: Useful or Useless?

Qinling Yang1, Sushun Liu2, Chaoling Deng2, Bo Shu2, Jingyao Zhang1, Mimi Zhai1.   

Abstract

Entities:  

Year:  2018        PMID: 30405841      PMCID: PMC6216009          DOI: 10.7150/jca.27497

Source DB:  PubMed          Journal:  J Cancer        ISSN: 1837-9664            Impact factor:   4.207


× No keyword cloud information.
We read the recent Journal of Cancer article published by Aryal et al with great interest 1. The author demonstrated that lower serum and intra-platelet (IP) 5-HT were closely related with higher recurrence rate after four weeks of operation. Additionally, serum and IP 5-HT could be used as the independent factors to predict the recurrence of hepatocellular carcinoma. However, the preoperative serum and IP 5-HT did not affect the recurrence in their study. The serum and IP 5-HT were even higher in non-recurrence patients before operation. We want to point out in contrary to the results which obtained by Aryal et al. High serum and IP 5-HT before liver resection both were closely related with poor prognosis including poor overall survival and poor recurrence -free survival. A study conducted by us demonstrated that high serum 5-HT, high IP 5-TH and high IP 5-HT per platelet were all associated with poor overall survival and recurrence-free survival via survival analysis among 113 HCC patients 2. Additionally, Padickakudy et al study also indicated that patients with excessively high IP 5-HT (>134 ng/ml) suffered an earlier recurrence 3 . A study conducted by Xia et al found that a preoperative elevated 5-HT was related with advanced tumor node metastasis and poor recurrence-free survival and overall survival via multivariate analysis 4. Additionally, high 5-HT was proved to be a marker for predicting the recurrence of breast cancer by Frobe et al 5. The peripheral 5-HT was mainly restored in the dense granules of platelets and was released after platelet activation. Thus, studies exploring the relationship between platelet and cancer recurrence could indirectly indicated the effects of 5-HT on cancer recurrence. Lee et al study showed that pretreatment platelet count was closely associated with extrahepatic metastasis of liver cancer and the Pang et al letter proposed that the platelet affected on extrahepatic metastasis of via platelet-derived serotonin 6, 7. Additionally, our previous study demonstrated that platelet count had the ability to predict postoperative recurrence of hepatocellular carcinoma 8. Moreover, 5-HT was proved to promote proliferation of hepatoma cell via basic research. Our previous study found that 5-HT promoted hepatoma cell proliferation via 5-HT-5-HT2BR-pERK-Yap axis 9. Besides, studies conducted by Soll et al and Liang et al were proved the serum-like and promotion effect of 5-HT on hepatoma cell 10-12. In conclusion, the preoperative level of 5-HT and IP 5-HT were higher in HCC patients. Furtherly, higher 5-HT and IP 5-HT level before treatment were both closely associated with poorer overall survival and recurrence-free survival. Thereby, 5-HT might be a potential therapeutic target. Because of the discrepancy with Aryal's results, more clinical researchers are needed to explore the level and effect of 5-HT and IP 5-HT on prognosis of HCC patients.
  12 in total

1.  Conflicting relationship between platelets and prognosis of hepatocellular carcinoma: is platelet-derived serotonin involved in?

Authors:  Qing Pang; Chang Liu; Kai Qu; Sushun Liu; Carmen Berasain
Journal:  Liver Int       Date:  2015-04-20       Impact factor: 5.828

2.  Bivalent role of intra-platelet serotonin in liver regeneration and tumor recurrence in humans.

Authors:  Robin Padickakudy; David Pereyra; Florian Offensperger; Philipp Jonas; Lukas Oehlberger; Christian Schwarz; Stefanie Haegele; Alice Assinger; Christine Brostjan; Thomas Gruenberger; Patrick Starlinger
Journal:  J Hepatol       Date:  2017-08-24       Impact factor: 25.083

3.  Pretreatment platelet count early predicts extrahepatic metastasis of human hepatoma.

Authors:  Chern-Horng Lee; Yu-Jr Lin; Chen-Chun Lin; Cho-Li Yen; Chien-Heng Shen; Chee-Jen Chang; Sen-Yung Hsieh
Journal:  Liver Int       Date:  2015-04-10       Impact factor: 5.828

4.  Intra-platelet serotonin in prognosis of tumorigenesis: Friend or foe?

Authors:  Bo Shu; Shuai Wang; Yan Deng; Mimi Zhai; Sushun Liu
Journal:  J Hepatol       Date:  2018-03-15       Impact factor: 25.083

5.  Serotonin promotes the proliferation of serum-deprived hepatocellular carcinoma cells via upregulation of FOXO3a.

Authors:  Chao Liang; Wei Chen; Xiao Zhi; Tao Ma; Xuefeng Xia; Hao Liu; Qi Zhang; Qida Hu; Yun Zhang; Xueli Bai; Tingbo Liang
Journal:  Mol Cancer       Date:  2013-02-19       Impact factor: 27.401

6.  Plasma serotonin level is a predictor for recurrence and poor prognosis in colorectal cancer patients.

Authors:  Yan Xia; Dawei Wang; Nan Zhang; Zhihao Wang; Li Pang
Journal:  J Clin Lab Anal       Date:  2017-05-22       Impact factor: 2.352

7.  Significance of platelet count and platelet-based models for hepatocellular carcinoma recurrence.

Authors:  Qing Pang; Jing-Yao Zhang; Xin-Sen Xu; Si-Dong Song; Kai Qu; Wei Chen; Yan-Yan Zhou; Run-Chen Miao; Su-Shun Liu; Ya-Feng Dong; Chang Liu
Journal:  World J Gastroenterol       Date:  2015-05-14       Impact factor: 5.742

8.  Serotonin promotes tumor growth in human hepatocellular cancer.

Authors:  Christopher Soll; Jae Hwi Jang; Marc-Oliver Riener; Wolfgang Moritz; Peter Johannes Wild; Rolf Graf; Pierre-Alain Clavien
Journal:  Hepatology       Date:  2010-04       Impact factor: 17.425

9.  Expression of serotonin receptors in human hepatocellular cancer.

Authors:  Christopher Soll; Marc-Oliver Riener; Christian Eugen Oberkofler; Claus Hellerbrand; Peter J Wild; Michelle L DeOliveira; Pierre-Alain Clavien
Journal:  Clin Cancer Res       Date:  2012-10-19       Impact factor: 12.531

10.  Effects and related mechanisms of serotonin on malignant biological behavior of hepatocellular carcinoma via regulation of Yap.

Authors:  Sushun Liu; Runchen Miao; Mimi Zhai; Qing Pang; Yan Deng; Sinan Liu; Kai Qu; Chang Liu; Jingyao Zhang
Journal:  Oncotarget       Date:  2017-07-18
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.